Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis. / Myken, Anders N.; Ebdrup, Bjørn H.; Sørensen, Mikkel E.; Broberg, Brian V.; Skjerbæk, Martin W.; Glenthøj, Birte Y.; Lykkesfeldt, Jens; Nielsen, Mette.

In: The international journal of neuropsychopharmacology, Vol. 25, No. 8, 2022, p. 613-618.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Myken, AN, Ebdrup, BH, Sørensen, ME, Broberg, BV, Skjerbæk, MW, Glenthøj, BY, Lykkesfeldt, J & Nielsen, M 2022, 'Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis', The international journal of neuropsychopharmacology, vol. 25, no. 8, pp. 613-618. https://doi.org/10.1093/ijnp/pyac029

APA

Myken, A. N., Ebdrup, B. H., Sørensen, M. E., Broberg, B. V., Skjerbæk, M. W., Glenthøj, B. Y., Lykkesfeldt, J., & Nielsen, M. (2022). Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis. The international journal of neuropsychopharmacology, 25(8), 613-618. https://doi.org/10.1093/ijnp/pyac029

Vancouver

Myken AN, Ebdrup BH, Sørensen ME, Broberg BV, Skjerbæk MW, Glenthøj BY et al. Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis. The international journal of neuropsychopharmacology. 2022;25(8):613-618. https://doi.org/10.1093/ijnp/pyac029

Author

Myken, Anders N. ; Ebdrup, Bjørn H. ; Sørensen, Mikkel E. ; Broberg, Brian V. ; Skjerbæk, Martin W. ; Glenthøj, Birte Y. ; Lykkesfeldt, Jens ; Nielsen, Mette. / Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis. In: The international journal of neuropsychopharmacology. 2022 ; Vol. 25, No. 8. pp. 613-618.

Bibtex

@article{be76dbd1617e47d7bfc0f721d90b7ac5,
title = "Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Na{\"i}ve Patients With First-Episode Psychosis",
abstract = "Low levels of vitamin C have been observed in patients with schizophrenia and psychosis, and vitamin C may affect the dopaminergic system. Likewise, antipsychotic medication modulates striatal dopamine D2 receptors. We measured vitamin C levels in 52 patients with first-episode psychoses (24 females, age 23.1 ± 5.2 years) and 57 matched HCs (20 females, age 22.7 ± 4.3 years) before and after 6 weeks where patients received aripiprazole monotherapy (mean dose 10.4 mg ± 4.8 mg). At baseline, patients displayed lower levels of vitamin C (57.4 ± 25.9 µM) than controls (72.7 ± 21.4 µM) (t = 3.4, P = .001). Baseline symptoms and vitamin C levels were not correlated. Higher baseline vitamin C levels were associated with more improvement in negative symptoms (n = 39, R2 = 0.20, F = 8.2, P = .007), but not with age, sex, or p-aripiprazole. Because negative symptoms are generally considered challenging to alleviate, a potential adjunctive effect of vitamin C on treatment response should be tested in future randomized clinical trials.",
keywords = "first-episode psychoses, negative symptoms, Vitamin C",
author = "Myken, {Anders N.} and Ebdrup, {Bj{\o}rn H.} and S{\o}rensen, {Mikkel E.} and Broberg, {Brian V.} and Skjerb{\ae}k, {Martin W.} and Glenth{\o}j, {Birte Y.} and Jens Lykkesfeldt and Mette Nielsen",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of CINP.",
year = "2022",
doi = "10.1093/ijnp/pyac029",
language = "English",
volume = "25",
pages = "613--618",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Oxford University Press",
number = "8",

}

RIS

TY - JOUR

T1 - Lower Vitamin C Levels Are Associated With Less Improvement in Negative Symptoms in Initially Antipsychotic-Naïve Patients With First-Episode Psychosis

AU - Myken, Anders N.

AU - Ebdrup, Bjørn H.

AU - Sørensen, Mikkel E.

AU - Broberg, Brian V.

AU - Skjerbæk, Martin W.

AU - Glenthøj, Birte Y.

AU - Lykkesfeldt, Jens

AU - Nielsen, Mette

N1 - Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of CINP.

PY - 2022

Y1 - 2022

N2 - Low levels of vitamin C have been observed in patients with schizophrenia and psychosis, and vitamin C may affect the dopaminergic system. Likewise, antipsychotic medication modulates striatal dopamine D2 receptors. We measured vitamin C levels in 52 patients with first-episode psychoses (24 females, age 23.1 ± 5.2 years) and 57 matched HCs (20 females, age 22.7 ± 4.3 years) before and after 6 weeks where patients received aripiprazole monotherapy (mean dose 10.4 mg ± 4.8 mg). At baseline, patients displayed lower levels of vitamin C (57.4 ± 25.9 µM) than controls (72.7 ± 21.4 µM) (t = 3.4, P = .001). Baseline symptoms and vitamin C levels were not correlated. Higher baseline vitamin C levels were associated with more improvement in negative symptoms (n = 39, R2 = 0.20, F = 8.2, P = .007), but not with age, sex, or p-aripiprazole. Because negative symptoms are generally considered challenging to alleviate, a potential adjunctive effect of vitamin C on treatment response should be tested in future randomized clinical trials.

AB - Low levels of vitamin C have been observed in patients with schizophrenia and psychosis, and vitamin C may affect the dopaminergic system. Likewise, antipsychotic medication modulates striatal dopamine D2 receptors. We measured vitamin C levels in 52 patients with first-episode psychoses (24 females, age 23.1 ± 5.2 years) and 57 matched HCs (20 females, age 22.7 ± 4.3 years) before and after 6 weeks where patients received aripiprazole monotherapy (mean dose 10.4 mg ± 4.8 mg). At baseline, patients displayed lower levels of vitamin C (57.4 ± 25.9 µM) than controls (72.7 ± 21.4 µM) (t = 3.4, P = .001). Baseline symptoms and vitamin C levels were not correlated. Higher baseline vitamin C levels were associated with more improvement in negative symptoms (n = 39, R2 = 0.20, F = 8.2, P = .007), but not with age, sex, or p-aripiprazole. Because negative symptoms are generally considered challenging to alleviate, a potential adjunctive effect of vitamin C on treatment response should be tested in future randomized clinical trials.

KW - first-episode psychoses

KW - negative symptoms

KW - Vitamin C

U2 - 10.1093/ijnp/pyac029

DO - 10.1093/ijnp/pyac029

M3 - Journal article

C2 - 35532335

AN - SCOPUS:85136908726

VL - 25

SP - 613

EP - 618

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 8

ER -

ID: 319400808